Lisinopril compound preparation and preparation method thereof

A compound preparation and preparation technology, which can be used in pharmaceutical formulations, medical preparations containing active ingredients, active ingredients of heterocyclic compounds, etc., can solve problems such as drug accumulation and non-binding effect of plasma proteins.

Inactive Publication Date: 2010-07-07
BEIJING HOPE HUGE PHARM SCI
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The decay of plasma drug concentration is prolonged terminal phase, but does not lead to drug accumulation, lisinopril seems to have no binding effect with other plasma proteins

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lisinopril compound preparation and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Embodiment 1: specification 1000 pieces

[0019] Prescription: Lisinopril 20g

[0020] Hydrochlorothiazide 12.5g

[0021] Lactose 25g

[0022] Microcrystalline Cellulose 40g

[0023] Mannitol 25g

[0024] Crospovidone 10g

[0025] Aspartame 0.1g

[0026] Fruit milk essence 0.1g

[0027] Micronized silica gel 0.75g

[0028] Magnesium stearate 0.75g

[0029] 30% ethanol solution of 8% povidone appropriate amount

[0030] Preparation method: take the prescribed amount of lisinopril, hydrochlorothiazide, microcrystalline cellulose, lactose, mannitol, and cross-linked povidone, sieve, mix evenly, and add an appropriate amount of 30% ethanol solution of 8% povidone to the above mixture Medium-made soft material, granulated through a 20-mesh sieve, dried at 60°C for 6 hours, granulated through a 20-mesh sieve, added fruit milk essence, magnesium stearate, aspartame, and micro-powdered silica gel, and granulated with a 30-mesh sieve. Mix well, compress into tablets or...

Embodiment 2

[0031] Embodiment 2: 1000 pieces of specifications

[0032] Lisinopril 10g

[0033] Hydrochlorothiazide 12.5g

[0034] Microcrystalline Cellulose 50g

[0035] Sodium carboxymethyl starch 2.5g

[0036] Lactose 20g

[0037] Mannitol 20g

[0038] Crospovidone 9g

[0039] Aspartame 0.1g

[0040] Fruit milk essence 0.1g

[0041] Micronized silica gel 0.75g

[0042] Magnesium stearate 0.75g

[0043] 30% ethanol solution of 8% povidone appropriate amount

[0044] Preparation method: take the prescribed amount of lisinopril, hydrochlorothiazide, microcrystalline cellulose, sodium carboxymethyl starch, lactose, mannitol, and crospovidone, sieve them, mix them evenly, and add an appropriate amount of 8% povidone 40 Add % ethanol solution to the above mixture to make soft material, pass through a 20-mesh sieve to granulate, dry at 60°C for 6 hours, granulate with a 20-mesh sieve, add fruit milk essence, magnesium stearate, aspartame, micropowder silica gel, and use 30 The purp...

Embodiment 3

[0045] Embodiment 3: 1000 pieces of specifications

[0046] Prescription: Lisinopril 20g

[0047] Hydrochlorothiazide 12.5g

[0048] Lactose 25g

[0049] Microcrystalline Cellulose 40g

[0050] Mannitol 25g

[0051] Crospovidone 10g

[0052] Aspartame 0.1g

[0053] Fruit milk essence 0.1g

[0054] Micronized silica gel 0.75g

[0055] Magnesium stearate 0.75g

[0056] 30% ethanol solution of 8% povidone appropriate amount

[0057] Preparation method: take the prescribed amount of lisinopril, hydrochlorothiazide, microcrystalline cellulose, lactose, mannitol, and cross-linked povidone, sieve, mix evenly, and add an appropriate amount of 30% ethanol solution of 8% povidone to the above mixture Medium-made soft material, granulated through a 20-mesh sieve, dried at 60°C for 6 hours, granulated through a 20-mesh sieve, added fruit milk essence, magnesium stearate, aspartame, and micro-powdered silica gel, and granulated with a 30-mesh sieve. Mix well, compress into tablets ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of pharmaceutical preparations, in particular to a lisinopril compound preparation and a preparation method thereof. The invention is used for treating various essential hypertension and secondary hypertension, and is especially suitable for essential hypertension and secondary hypertension accompanied by diabetes, renal hypertension and congestive heart failure.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a lisinopril compound preparation and a preparation method thereof. Background technique [0002] Hypertension is one of the most common and important cardiovascular diseases in clinical practice. With the continuous improvement of people's living standards, the prevalence of hypertension is also increasing year by year. The prevalence of hypertension in adults has risen from 5.1% in 1959 to 11.68% at present. On the one hand, hypertension can be a clinical manifestation caused by different reasons and diseases, and on the other hand, it can be used as a cause to cause damage to important organs such as the heart, brain, and kidneys. The secondary heart, brain, kidney and other target organ damage caused by high blood pressure have seriously affected the life expectancy and quality of life of patients and have become a serious threat to human health and life. [0003]...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/549A61K31/40A61P9/12
Inventor 王翰斌王翰腾
Owner BEIJING HOPE HUGE PHARM SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap